Saurabh Kapadia

If I look at the payer mix, there has been increase in the scheme patients, both CGHS and ECHS. So, how should we look at the mix of the scheme patients going ahead with no beds getting added over the next 6 to 9 months?

But new beds addition will not lead to higher scheme patients?

And do you see any impact on the international patients because of the Bangladesh situation?

So first question is on ARPOB so another 19% kind of growth can we sustain? And also, do we have levers further to improve on it given that a few beds additions are coming in.

Okay. And this bed addition will lead to some dilution in the payer mix for next year? That would be the assumption?

Okay. And my second question is on the medical talent…